Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.

Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J.

BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789.

2.

Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.

Michalopoulos SN, Kella N, Payne R, Yohannes P, Singh A, Hettinger C, Yousefi K, Hornberger J; PRO-ACT Study Group..

Curr Med Res Opin. 2014 Aug;30(8):1547-56. doi: 10.1185/03007995.2014.919908.

PMID:
24803160
3.

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.

Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J.

Oncotarget. 2013 Apr;4(4):600-9.

4.

Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists.

Nguyen PL, Shin H, Yousefi K, Thompson DJ, Hornberger J, Hyatt AS, Badani KK, Morgan TM, Feng FY.

Urology. 2015 Jul;86(1):35-40. doi: 10.1016/j.urology.2015.04.004.

PMID:
26142578
5.

A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.

Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036.

PMID:
25466945
6.

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ.

J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.

7.

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB.

J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017.

8.

Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.

Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM.

Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042.

PMID:
26058959
9.

Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.

Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1038-46. doi: 10.1016/j.ijrobp.2014.04.052.

10.

Knowledge, attitudes and beliefs towards management of men with locally advanced prostate cancer following radical prostatectomy: an Australian survey of urologists.

Brown B, Young J, Kneebone AB, Brooks AJ, Dominello A, Haines M.

BJU Int. 2016 Apr;117 Suppl 4:35-44. doi: 10.1111/bju.13037.

PMID:
25585989
11.

Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry.

Evans SM, Millar JL, Frydenberg M, Murphy DG, Davis ID, Spelman T, Bolton DM, Giles GG, Dean J, Costello AJ, Frauman AG, Kearns PA, Day L, Daniels C, McNeill JJ.

BJU Int. 2014 Nov;114(5):680-90. doi: 10.1111/bju.12509.

12.

Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.

van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I, Steyerberg EW.

BJU Int. 2012 Jul;110(2):180-7. doi: 10.1111/j.1464-410X.2011.10679.x.

13.

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):64-9. doi: 10.1038/pcan.2013.49.

14.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x.

15.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030.

16.

Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.

Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Jul 30. pii: S0302-2838(16)30433-X. doi: 10.1016/j.eururo.2016.07.028. [Epub ahead of print]

PMID:
27484843
17.
18.

Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.

Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017.

PMID:
25294696
19.

Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.

Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT.

J Urol. 2005 Sep;174(3):903-7.

PMID:
16093984
20.

Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.

Ariane MM, Ploussard G, Rebillard X, Malavaud B, Rischmann P, Hennequin C, Mongiat-Artus P.

World J Urol. 2015 Nov;33(11):1741-7. doi: 10.1007/s00345-015-1543-2.

PMID:
25822706
Items per page

Supplemental Content

Support Center